Journal of Clinical Oncology · 1994 · 154 citations · 14 references
MedicineCardiologyNuclear MedicineCardiac Nuclear MedicineCardiac TransplantationStem Cell TransplantationBone Marrow EvaluationCardiotoxicity ManagementHeart FailureTransplant ComplicationsTransplant OutcomesTransplant-related ToxicitiesAcute Cardiac ToxicityCardiac Physical ExaminationHematopoietic Stem Cell Transplant Cardiac ComplicationsHematopoietic Stem Cell Transplant CardiotoxicityLeft Ventricular Ejection Fraction DeclineLeft Ventricular FailureTwo-dimensional EchocardiographyVentricular Ejection Fraction Assessment
PURPOSE: This study analyses the risk of cardiac complications and its individual predictability in bone marrow transplantation (BMT). PATIENTS AND METHODS: One hundred seventy patients undergoing allogeneic (n = 150) or autologous (n = 20) BMT were evaluated by physical examination, history, rest and exercise ECG, chest x-ray, two-dimensional echocardiography, and radionuclide ventriculography (RNV) before BMT, and monitored for 3 months thereafter. RESULTS: Following BMT, cardiac toxicity occurred in eight patients (4.7%). Three patients (1.8%) developed life-threatening toxicity (pericardial effusion and left ventricular failure, n = 2; sudden cardiac arrest, n = 1). Thirty-eight patients (22%) had pathologic findings before BMT. In 22 patients, left ventricular ejection fraction (EF) determined by RNV was reduced to less than 55%. This was the only abnormality in 17 patients and was generally mild, with a lowest EF of 42%. There was no correlation between overall results of cardiologic evaluation before BMT and cardiac toxicity. Cardiotoxic events occurred more frequently in patients with a reduced EF (P < .05). However, this was restricted to minor cardiac events. Life-threatening cardiac toxicity was not significantly increased in patients with pathologic results before BMT. Moreover, none of the patients with an EF less than 50% developed cardiac toxicity. CONCLUSION: Life-threatening cardiac toxicity is rare after BMT, occurring in less than 2% of all patients. Although the occurrence of cardiac toxicity is correlated with a reduction of EF before BMT, life-threatening cardiac toxicity cannot be predicted in individual patients.
14
Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
MA Goldberg, JH Antin, EC Guinan et al. · Blood · 1986 · 359 citations · Full text
Medicine, Pharmacology, Toxicology +14
Adriamycin cardiomyopathy—risk factors
Robert A. Minow, Robert S. Benjamin, Elisa T. Lee et al. · Cancer · 1977 · 253 citations · Full text
Medicine, Cardiology, Pharmacology +17
ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPY
FrederickR Appelbaum, JamesA Strauchen, R. G. Graw et al. · The Lancet · 1976 · 173 citations